Evidence map›Paper›PMID 41555052›Full record

ArticleDiabetologia2026

Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass.

Sevilay Tokgöz, Laura N Deden, Adrianne Hofboer, Rick I Meijer, Eric J Hazebroek, Arianne C van Bon, Bastiaan E de Galan, Cees J Tack, Marti Boss, Martin Gotthardt

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02542059 (Visualizing Beta Cells in Patients With Remission of T2DM After Bariatric Surgery), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02542059 unknown statusnot on this map

Visualizing Beta Cells in Patients With Remission of T2DM After Bariatric Surgery

TypeobservationalSponsorRadboud University Medical CenterRan2015 to 2024Enrolled24ConditionsType 2 Diabetes MellitusArms68Ga-exendin PET/CT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sevilay TokgözDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. Sevilay.Tokgoz@radboudumc.nl.ORCID http://orcid.org/0009-0009-7597-8170
Laura N DedenDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-1243-5111
Adrianne HofboerDepartment of Surgery, Rijnstate Hospital, Arnhem, the Netherlands.
Rick I MeijerDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-5360-5439
Eric J HazebroekDepartment of Surgery, Rijnstate Hospital, Arnhem, the Netherlands.ORCID http://orcid.org/0000-0001-5458-3334
Arianne C van BonDepartment of Internal Medicine, Rijnstate Hospital, Arnhem, the Netherlands.
Bastiaan E de GalanDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-1255-7741
Cees J TackDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0003-0322-1653
Marti BossDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-5837-1803
Martin GotthardtDepartment of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-6537-7744

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisIn people with type 2 diabetes and obesity, Roux-en-Y gastric bypass (RYGB) can induce remission of diabetes. While RYGB has been reported to improve beta cell function in individuals with type 2 diabetes, it is unclear whether this is accompanied by changes in beta cell mass. In this explorative proof-of-concept study, we compared beta cell mass, measured by [

methodsIndividuals with (n=8) and without (n=9) remission of type 2 diabetes up to 4 years after RYGB were injected with 100 ± 5.6 MBq of [

resultsIndividuals with remission of type 2 diabetes had a shorter diabetes duration than those without remission. After RYGB, beta cell function was higher in individuals with remission of type 2 diabetes than individuals without remission, based on both ARGTs (AUC CONCLUSIONS/

interpretationIndividuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. Our preliminary data argue against a stimulating effect of RYGB on beta cell mass, although revival of non-functional (so-called dormant) beta cells is a possible explanation for remission.

trial registrationClinicalTrials.gov NCT02542059.

Indexed as

Diabetes Mellitus, Type 2Gastric BypassInsulin-Secreting CellsAdultBlood GlucoseC-PeptideFemaleHumansMaleMiddle AgedObesityPositron Emission Tomography Computed TomographyRemission InductionBlood GlucoseC-PeptideBariatric surgeryBeta cell functionBeta cell massExendinMolecular imagingPET imagingRYGBType 2 diabetes

Identifiers

PMID41555052
PMCPMC13005773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.